[{"id":"6e2d07bb-ff82-4aba-b019-e034b92f6ad5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02149225","created_at":"2021-01-18T09:59:12.536Z","updated_at":"2024-07-02T16:37:08.190Z","phase":"Phase 1","brief_title":"GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients","source_id_and_acronym":"NCT02149225","lead_sponsor":"Immatics Biotechnologies GmbH","biomarkers":" HLA-A • CSF2","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • APVAC1 vaccine • Hiltonol (poly-ICLC) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-08-07"}]